4142.TW TAI
Adimmune Corporation
1W: -0.6%
1M: -2.8%
3M: -7.1%
YTD: -3.6%
1Y: -12.4%
3Y: -57.2%
5Y: -65.2%
NT$17.50 ($0.56)
-0.10 (-0.57%)
Weekly Expected Move ±3.1%
NT$16
NT$17
NT$17
NT$18
NT$18
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market CapNT$7.4B ($234.6M)
52W Range15.9-22.5
Volume1,157,478
Avg Volume1,368,234
Beta0.30
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOChi-Hsien Chan
Employees564
SectorHealthcare
IndustryBiotechnology
IPO Date2012-05-03
Websiteadimmune.com.tw
No. 3, Tanxing Road
Taichung 427003
TW
Taichung 427003
TW
886 4 2538 1220
About Adimmune Corporation
Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is headquartered in Taichung, Taiwan.
Latest News
No recent news
Recent Insider Trades
No insider trades found